Movement Disorders

Here's some of what is coming soon to NeurologyLive® this week.

Real-world survey data suggest deutetrabenazine treatment may be associated with improvements in patient- and caregiver-reported quality-of-life outcomes among individuals with Huntington disease chorea.

The CEO and founder of Yes, And...eXercise (YAX) discussed how support groups, psychosocial connection, and hybrid telehealth models can complement pharmacologic treatment in Parkinson disease. [WATCH TIME: 3 minutes]

Exploratory post hoc data suggest prompt pimavanserin initiation within 6 to 12 months of PDP onset may yield a more favorable symptom trajectory, though prospective confirmation is needed.

In this final episode, Roger Barker, MD, PhD, and Claire Henchcliffe, MD, DPhil, discuss why neurologists should stay informed on stem cell medicine and the broader implications of regenerative therapies across neurology.

Neurologists Roger Barker, MD, PhD, and Claire Henchcliffe, MD, DPhil, discuss how stem cell therapies may differ from existing Parkinson disease treatments and the potential benefits of dopamine cell replacement.

Roger Barker, MD, PhD, and Claire Henchcliffe, MD, DPhil, examine the expanding clinical trial landscape for stem cell therapies in Parkinson disease and the programs leading development efforts.

12-montn interim findings from an ongoing phase 1/2 study showed up to 69% reductions in mutant huntingtin protein and favorable cUHDRS trends with the investigational oral RNA-splicing modifier SKY-0515.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 29, 2026.

Joohi Jimenez-Shahed, MD, professor of neurology at Mount Sinai, commented on the evolving understanding of Tourette syndrome, persistent misconceptions, and emerging therapeutic and neuromodulation approaches for tic disorders.

Here's some of what is coming soon to NeurologyLive® this week.

Amlenetug, a monoclonal antibody targeting aggregated α-synuclein, showed a nonsignificant slowing of clinical progression compared with placebo and was generally well tolerated in patients with MSA.

A newly published analysis proposed a 4-point Tardive Dyskinesia Impact Scale (TDIS) threshold to interpret patient-reported improvement in patients living with tardive dyskinesia.

Hybridopa improved MDS-UPDRS scores in a small phase 2a Parkinson disease trial, with phase 3 testing planned for 2026.

New phase 4 head-to-head data suggest Dysport may provide longer-lasting symptom control than Botox in adults with upper limb spasticity while maintaining comparable safety.

The FDA's acceptance and priority review of levacetylleucine for ataxia-telangiectasia positions the therapy to potentially become the first approved treatment for the rare neurodegenerative disorder.

Here's some of what is coming soon to NeurologyLive® this week.

Kelsey Jensen, MD, a movement disorders neurologist at Allina Health, discussed Parkinson disease diagnosis, deep brain stimulation candidacy, treatment personalization, and ongoing unmet needs in PD care and research.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 15, 2026.

Experts shared their clinical perspectives and insights on main focus areas at the 2026 American Academy of Neurology (AAN) Annual Meeting, held April 18-22 in Chicago, Illinois.

James Beck, PhD, of the Parkinson’s Foundation, and Ben Casavant, PhD, of Tasso discuss new PD GENEration findings, the growing role of genetic testing in Parkinson disease, and how at-home blood collection may expand participation in neurologic research.

Kristine Yaffe, MD, distinguished professor at UCSF and SEQUINS Hall of Fame honoree, discusses dementia prevention, modifiable risk factors, and ongoing disparities in brain health and cognitive aging.

As a 2026 SEQUINS Hall of Fame honoree, James Galvin, MD, MPH, reflected on advancing equitable dementia care, culturally relevant cognitive assessment, and improving brain health outcomes across diverse communities.

As a 2026 SEQUINS Hall of Fame honoree, George Howard, DrPH, commented on decades of stroke disparities research, the impact of the REGARDS study, and why future efforts must focus more directly on upstream risk factors.